InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL
Unusual Whales
A recent study published in the journal STTT found that orelabrutinib leads to a significant extension in progression-free survival (PFS) and decreases the likelihood of disease progression or mortality by 68%.
